PUNE, India, April 1, 2016 /PRNewswire/ --
New market research report titled, "Diarrhea - Pipeline Review, H1 2016," provides an overview on therapeutic pipeline of Diarrhea while helping enhance decision making capabilities and create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes A. Menarini Industrie Farmaceutiche Riunite Srl, Ache Laboratorios Farmaceuticos S/A, Actelion Ltd, Aegis Therapeutics, LLC, Akthelia Pharmaceuticals Limited, AlbireoPharma, Allergan Plc, Anatara Lifesciences Limited, Ardelyx, Inc., Assembly Biosciences, Inc., Chiesi Farmaceutici SpA, Cosmo Pharmaceuticals S.p.A, DesignMedix, Inc., DiscoveryBiomed, Inc., Genexine, Inc., GlaxoSmithKline Plc, GP Pharm, S.A., Helsinn Healthcare S.A., Intercept Pharmaceuticals, Inc., Merck & Co., Inc., Mucosis B.V., Nippon Shinyaku Co., Ltd., Novartis AG, Pfizer Inc., Prokarium Limited, Protagonist Therapeutics Inc., Rebiotix Inc., RxBio, Inc., Sanofi Pasteur SA, Scandinavian Biopharma Holding AB, Shire Plc, Sigmoid Pharma Limited, Summit Therapeutics Plc, Synthetic Biologics, Inc. and Syntiron LLC.
Complete report on H1 2016 pipeline review of Diarrhea with 58 market data tables and 16 figures, spread across 186 pages is available at http://www.rnrmarketresearch.com/diarrhea-pipeline-review-h1-2016-market-report.html .
Drugs Profiles discussed in this report includes ABM-101, ACE-527, ACE-920, ACH-04, AKT-10081, ASP-7147, cadazolid, Campylobacter jejuni [strain CPS81-176] vaccine, cholestyramine, Clostridium difficile vaccine, crofelemer DR, Drug for Diarrhea, elsiglutide, eluxadoline, Escherichia coli vaccine, ETEC vaccine, Etvax, fidaxomicin, GVXNSD-133, GXG-8, Helicobacter pylori [strain Hel-305] (multivalent) vaccine, ibodutant, IMSUTMR-1501, infectious diarrhea [serotype H11] vaccine, obeticholic acid, octreotide acetate, octreotide acetate MAR, Peptide to Activate NHE-3 for Diarrhea, PF-06425090, prulifloxacin, PZ-7475, RBX-2660, RDX-009, Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea, Recombinant Proteins for Infectious Diarrhea, ridinilazole, rifamycin CR, Rx-100, Small Molecule to Block CFTR for Diarrhoea, Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease, Small Molecules for Microbial Infections, Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea, Small Molecules to Inhibit CFTR for Secretory Diarrhea, surotomycin, SYN-004, Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea, Typhetec, Vaccine 1 for Diarrhea, Vaccine 2 for Diarrhea, Vaccine for Traveler's Diarrhea, Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea, VP-20621 and Yersinia pestis vaccine.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=516268 .
This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Diarrhea and reviews pipeline therapeutics for Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Diarrhea therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Diarrhea.
Another newly published market research report titled on Plague - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Plague Pipeline market research 2016 report of 66 pages is available at http://www.rnrmarketresearch.com/plague-pipeline-review-h1-2016-market-report.html .
More reports on Therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE RnR Market Research